Financial Performance - For the six months ended June 30, 2023, the total revenue was RMB 410.726 million, an increase of 5.1% compared to RMB 389.825 million for the same period in 2022[19]. - The pharmaceutical sales amounted to RMB 395.636 million, up from RMB 377.295 million, reflecting a growth of 4.0% year-over-year[19]. - The company's revenue for the six months ended June 30, 2023, was RMB 395,636 thousand, representing an increase of 4.4% compared to RMB 377,295 thousand for the same period in 2022[23]. - The net profit attributable to shareholders for the six months ended June 30, 2023, was RMB 80,848 thousand, up from RMB 77,255 thousand in 2022, marking an increase of 3.4%[23]. - Operating profit increased to RMB 107,137 thousand for the six months ended June 30, 2023, compared to RMB 92,043 thousand in 2022, reflecting a growth of 16.4%[23]. - Gross profit for the same period was RMB 266,027 thousand, down from RMB 297,844 thousand in 2022, indicating a decrease of 10.5%[23]. - The basic earnings per share for the six months ended June 30, 2023, was 14.43 cents, compared to 13.79 cents for the same period in 2022, representing a growth of 4.6%[23]. - The income tax expense for the six months ended June 30, 2023, was RMB 24,500,000, compared to RMB 14,152,000 for the same period in 2022, indicating a year-over-year increase of approximately 73.5%[59]. Assets and Liabilities - The net current assets totaled RMB 1,604.252 million as of June 30, 2023, slightly down from RMB 1,612.298 million at the end of 2022[14]. - The total non-current assets decreased to RMB 461.953 million from RMB 605.364 million, indicating a decline of 23.7%[11]. - The company reported a total asset value of RMB 1,646,000 thousand as of June 30, 2023, compared to RMB 1,646,000 thousand as of December 31, 2022, indicating stability in asset management[25]. - Cash and cash equivalents decreased to RMB 93,839 thousand as of June 30, 2023, from RMB 113,601 thousand as of December 31, 2022, a decline of 17.4%[25]. - The company's inventory as of June 30, 2023, was RMB 113,511,000, down from RMB 132,987,000 as of December 31, 2022[96]. - Trade receivables as of June 30, 2023, totaled RMB 275,832,000, a slight decrease from RMB 282,506,000 as of December 31, 2022[97]. - The company had no significant or contingent liabilities as of June 30, 2023[104]. - As of June 30, 2023, the company had zero short-term bank borrowings, maintaining a capital debt ratio of approximately 0%[105]. Operational Efficiency - The company continues to focus on enhancing its operational efficiency and exploring new market opportunities to drive future growth[23]. - Selling expenses as a percentage of revenue decreased to 36.96% for the six months ended June 30, 2023, down from 46.6% in the same period of 2022[80]. - General and administrative expenses decreased from RMB 42,275,000 for the six months ended June 30, 2022, to RMB 27,771,000 for the same period in 2023[80]. - The company maintained a stable financial position, with cash generated from operations being the primary source of funding as of June 30, 2023[81]. Corporate Governance - The company has not repurchased, sold, or redeemed any of its listed shares during the reporting period[6]. - The company has not disclosed any new product developments or market expansion strategies in the current report[10]. - There are no significant mergers or acquisitions reported during the period[10]. - The Audit Committee consists entirely of independent non-executive directors, ensuring compliance with GEM listing rules[122]. - The company has reviewed its accounting policies and internal controls, discussing financial reporting matters for the period ending June 30, 2023[124]. - The company has a total of 6 executive directors and 3 independent non-executive directors on its board[127]. Market Environment - The company continues to operate in a high-risk investment environment as indicated by its listing on the GEM market, which is characterized by higher volatility[21]. - The company aims to develop potential business opportunities to drive growth and achieve better performance in the future[107]. - The company has officially commenced production in its small capacity injection workshop, increasing production capacity[101]. - The consistency evaluation for the Yidalapeng injection has passed, and it has entered the seventh batch of national centralized procurement[101]. Employment - As of June 30, 2023, the group employed 928 staff members, a decrease from 956 staff members on June 30, 2022[115]. - The company has a major shareholder, Mr. Zhang Hong, holding 101,937,000 shares, representing 26.29% of the domestic shares and 18.19% of the total registered capital[117].
吉林长龙药业(08049) - 2023 - 中期业绩